|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Alfacell Corp., of Bloomfield, N.J., said an article in the May 2003 issue of Laboratory Medicine evaluated the company's flagship product, Onconase. The article summarized preclinical findings relating to the structure and mechanical mechanisms of the drug, as well as its use in the growth of targeted therapies. Onconase is scheduled to be evaluated in a federal program against the human coronavirus implicated in SARS. The drug is designed to work by irreparably destroying RNA.
o Altus Biologics Inc., of Cambridge, Mass., said results from a Phase I trial of its enzyme replacement therapy, TheraCLEC, showed it to be safe and tolerable across a range of doses. ...